annamycin

annamycin

Oncology A liposomal anthracycline for treating CAs–eg multiple-drug-resistant tumors–eg, refractory breast CA, refractory/relapsed AML, ALL, blast crisis of CML. See Anthracycline, Liposomes.
References in periodicals archive ?
The Company's clinical stage drugs are: Annamycin, a Next Generation Anthracycline, designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studied for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic cancer and hematologic malignancies, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma.
Moleculin Biotech announced additional positive interim safety and efficacy data from its ongoing open label, single arm Phase 1/2 study of Annamycin in Poland.
M2 EQUITYBITES-March 23, 2017-Moleculin awarded orphan drug designation for Annamycin to treat acute myeloid leukemia
M2 PHARMA-March 23, 2017-Moleculin awarded orphan drug designation for Annamycin to treat acute myeloid leukemia
("Dermin") to use the latter's supply of Annamycin for its proposed clinical trial.
Many anti-cancer agents such as doxorubicin, daunorubicin, annamycin, vincristine, paclitaxel and cisplatin, camptothecin and 5-fluorouracil derivatives have been successfully encapsulated in liposomes.
And his early work on Annamycin, a drug that we recently in-licensed from M.D.
Klemp continued, 'was the announcement of additional positive safety and efficacy data from our ongoing Phase 1/2 study - in Poland - of Annamycin for the treatment of acute myeloid leukemia, and consequently the advancement to our third cohort of patients to be treated.
The phase 1/2 clinical trial now underway in Poland for the company's Annamycin compound has shown "promising" results with one trial patient's acute myeloid leukemia now in remission, making the patient eligible for a bone marrow transplant.
Moleculin Biotech's ongoing sponsored research at The University of Texas MD Anderson Cancer Center has demonstrated that Annamycin is able to significantly improve survival in an aggressive form of triple negative breast cancer metastasized to the lungs in animal models.
Moleculin Biotech announced positive interim safety and efficacy data from two ongoing open label, single arm Phase 1/2 studies of Annamycin. In the first study, being conducted in the US, four patients have completed treatment at 100 mg/m2 with no significant adverse events related to Annamycin, and the study will now proceed to the next higher dose of 120 mg/m2.
This follows the Company's announcement in June of this year of the approval of a CTA in Poland for its drug Annamycin for the treatment of acute myeloid leukemia.